Drug Pricing
Commentary
A Bipartisan Regulatory Reform Opportunity: 340B
Despite the rancor, there are many bipartisan opportunities for the divided 118th Congress. Near the top of the to-do list should be reforming the well-intentioned, but poorly designed, 340B drug discount program. 340B enables qualifying institutions to purchase medicines from manufacturers at steep discounts, generally between 25% and 50% off list ...
Blog
Key Takeaways from President Biden’s Proposed 2024 Healthcare Budget
The United States currently faces a deficit of over $700 billion. Not including other health programs, in 2021, over $734 billion was spent on Medicaid alone. Despite these facts, President Biden’s 2024 budget proposal aims to increase funding for healthcare by 11.5%. The proposal claims proposed tax increases will not ...
Commentary
How The Republican House Can Prevent Medicare Price Controls From Becoming Death Sentences
The Inflation Reduction Act’s (IRA) drug pricing provisions will severely curtail life-science research. The IRA vests the Centers for Medicare & Medicaid Services with the power to impose price controls on an ever-expanding list of drugs. The direct result will be that seniors today — as well as future generations ...
Commentary
Diversifying America’s supply chains point to a more prosperous economic future
Rep. Cathy McMorris Rodgers, R-Wash., the chair of the powerful House Energy and Commerce Committee, recently warned that the United States is “dangerously dependent” on Chinese supply chains, especially for the raw materials used to make medicines. Her statement reflects the genuine worries of industry experts and ordinary Americans. If ...
Commentary
Democrats’ Price Controls Undermine Biden’s Cancer Moonshot
Last night’s State of the Union address was a festival of cognitive dissonance. President Biden proudly lauded the price controls that Democrats have begun implementing on prescription drugs as part of last August’s Inflation Reduction Act. He also touted his administration’s Cancer Moonshot, which aims to halve the cancer death rate ...
Commentary
Grave Mistake to Fix Drug Prices Without Esteem for Their Value
Democrats remain fixated on prescription drug prices. Last August, they managed to include price controls on drugs dispensed through Medicare in the Inflation Reduction Act. And they’re not done meddling. Earlier this month, Rep. Lloyd Doggett, D-Texas, called on President Biden to unilaterally suspend drug patents in order “to address the crisis ...
Commentary
How to give patients a right to save on health care
Shopping around has never been easier. With a few clicks, consumers can easily find deals on flights, get multiple quotes on car insurance or price-match items in their local shopping mall. Yet when it comes to spending money on something really important — their health — consumers are largely in ...
Drug Pricing
NEW BRIEF: Empowering Providers to Promote Healthcare Innovation
These reforms include: Implementing the insurance reforms discussed in Part 5 that, from a provider perspective, will incentivize the creation of innovative payment models. New payment models create opportunities to better align the incentives of providers and patients. Implementing regulatory reforms that include eliminating certificate of need laws, scope ...
Commentary
Price Controls, Publicly Funded Insurance Won’t Deliver Value
On Dec. 14, the Centers for Medicare and Medicaid Services (cms.gov) released their latest estimate of the country’s annual healthcare tab. For the second straight year, U.S. healthcare spending topped $4 trillion. In 2021, health spending accounted for more than 18% of U.S. GDP. Progressives tend to cite numbers like these ...
Commentary
An Effective Treatment for Alzheimer’s, But Only if ICER Allows It
Three days before Christmas, the Institute for Clinical & Economic Review (ICER) is scheduled to publish a draft assessment of two promising treatments for Alzheimer’s disease. Unfortunately for the millions of Americans living with this fatal illness, it is likely that ICER will be giving lumps of coal, not gifts, ...
A Bipartisan Regulatory Reform Opportunity: 340B
Despite the rancor, there are many bipartisan opportunities for the divided 118th Congress. Near the top of the to-do list should be reforming the well-intentioned, but poorly designed, 340B drug discount program. 340B enables qualifying institutions to purchase medicines from manufacturers at steep discounts, generally between 25% and 50% off list ...
Key Takeaways from President Biden’s Proposed 2024 Healthcare Budget
The United States currently faces a deficit of over $700 billion. Not including other health programs, in 2021, over $734 billion was spent on Medicaid alone. Despite these facts, President Biden’s 2024 budget proposal aims to increase funding for healthcare by 11.5%. The proposal claims proposed tax increases will not ...
How The Republican House Can Prevent Medicare Price Controls From Becoming Death Sentences
The Inflation Reduction Act’s (IRA) drug pricing provisions will severely curtail life-science research. The IRA vests the Centers for Medicare & Medicaid Services with the power to impose price controls on an ever-expanding list of drugs. The direct result will be that seniors today — as well as future generations ...
Diversifying America’s supply chains point to a more prosperous economic future
Rep. Cathy McMorris Rodgers, R-Wash., the chair of the powerful House Energy and Commerce Committee, recently warned that the United States is “dangerously dependent” on Chinese supply chains, especially for the raw materials used to make medicines. Her statement reflects the genuine worries of industry experts and ordinary Americans. If ...
Democrats’ Price Controls Undermine Biden’s Cancer Moonshot
Last night’s State of the Union address was a festival of cognitive dissonance. President Biden proudly lauded the price controls that Democrats have begun implementing on prescription drugs as part of last August’s Inflation Reduction Act. He also touted his administration’s Cancer Moonshot, which aims to halve the cancer death rate ...
Grave Mistake to Fix Drug Prices Without Esteem for Their Value
Democrats remain fixated on prescription drug prices. Last August, they managed to include price controls on drugs dispensed through Medicare in the Inflation Reduction Act. And they’re not done meddling. Earlier this month, Rep. Lloyd Doggett, D-Texas, called on President Biden to unilaterally suspend drug patents in order “to address the crisis ...
How to give patients a right to save on health care
Shopping around has never been easier. With a few clicks, consumers can easily find deals on flights, get multiple quotes on car insurance or price-match items in their local shopping mall. Yet when it comes to spending money on something really important — their health — consumers are largely in ...
NEW BRIEF: Empowering Providers to Promote Healthcare Innovation
These reforms include: Implementing the insurance reforms discussed in Part 5 that, from a provider perspective, will incentivize the creation of innovative payment models. New payment models create opportunities to better align the incentives of providers and patients. Implementing regulatory reforms that include eliminating certificate of need laws, scope ...
Price Controls, Publicly Funded Insurance Won’t Deliver Value
On Dec. 14, the Centers for Medicare and Medicaid Services (cms.gov) released their latest estimate of the country’s annual healthcare tab. For the second straight year, U.S. healthcare spending topped $4 trillion. In 2021, health spending accounted for more than 18% of U.S. GDP. Progressives tend to cite numbers like these ...
An Effective Treatment for Alzheimer’s, But Only if ICER Allows It
Three days before Christmas, the Institute for Clinical & Economic Review (ICER) is scheduled to publish a draft assessment of two promising treatments for Alzheimer’s disease. Unfortunately for the millions of Americans living with this fatal illness, it is likely that ICER will be giving lumps of coal, not gifts, ...
